All
Candida antifungal performs well in study
April 1st 2005An investigational topical antifungal product containing miconazole nitrate 0.25 percent in a petrolatum/zinc oxide barrier ointment base (Zimycan, Barrier Therapeutics) has demonstrated positive efficacy and safety results in a phase 3 study of the treatment of Candida diaper dermatitis.
Superficial peds infections abound
April 1st 2005New Orleans - In today's global, transient and sometimes overcrowded society, the spread of superficial cutaneous infections and infestations in children appears to be even more common than previously thought. International travel, immigration and foreign adoption have altered the typical distribution of some pediatric infections and infestations.
Advances aid treatment in pediatric dermatology
April 1st 2005There have been a number of important advances in pediatric dermatology, ranging from finding the optimal use for tissue adhesives to gaining a better understanding of general and local anesthetic use in the pediatric population and a greater appreciation for dermatologic surgeons' roles in treating vascular lesions and birthmarks.
Accurate, timely diagnosis of dermatoses in children critical
April 1st 2005New Orleans — Rare, life-threatening dermatoses are presenting in pediatric patients across the country, and some dermatologists are missing these critical diagnoses, according to Patricia Treadwell, M.D., professor of pediatrics, Riley Hospital for Children, Indianapolis.
Use of poly-L-lactic acid shows promise as treatment for lipodystrophic facial aging
April 1st 2005New Orleans — Initial clinical experience indicates injectable poly-L-lactic acid (Sculptra) can be used safely and effectively to achieve natural-appearing restoration of facial volume and contour in patients with age-related facial lipodystrophy, said Douglas Key, M.D., at the 63rd Annual Meeting of the American Academy of Dermatology (AAD) here.
Derm projects range of HA products will provide toolsfor lunchtime filling
April 1st 2005Boston — Although, for many patients, hyaluronic acid (HA) fillers have become the treatment of choice in the United States, Gary D. Monheit, M.D., says many questions remain: Can Hylaform (Inamed), Restylane (Q-Med) and Juvederm (LEA Derm) be improved to achieve more than a three- to six-month longevity? How will the fillers compare after more extensive head-to-head testing? And where will HA products ultimately fit in an armamentarium ranging from bovine collagen to polylactic acid?
Anidulafungin effective against ARMC
April 1st 2005Washington — Anidulafungin (Vicuron, Vicuron Pharmaceuticals Inc.), a new echinocandin presently being developed for the treatment of serious fungal infections, has been shown to be effective and well-tolerated in a large majority of patients who have azole-refractory mucosal candidiasis (ARMC), said Jennifer A. Schranz, M.D., in a presentation at the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy here.
Safe, effective hemostasis mandates
April 1st 2005New Orleans — Careful preoperative assessment to identify risk factors for increased perioperative bleeding, meticulous surgical technique to gain control of vessels and appropriate use of surgical adjuncts form the foundation for safe and effective hemostasis in dermatologic surgery, says David E. Kent, M.D., at the 63rd Annual Meeting of the American Academy of Dermatology.
Surgeon offers pearls for keloid tx
April 1st 2005Los Angeles — For stubborn keloids that do not respond to intralesional triamcinolone acetonide (Kenalog, Bristol-Myers Squibb), especially post-CABG sternal keloids, William V.R. Shellow, M.D., has successfully used methylprednisolone acetate (Depo-Medrol, Pharmacia & Upjohn), normally used by orthopedists for injecting joints.
Alternative treatments for alopecia areata
April 1st 2005Florence — Alopecia areata is a disease with important aesthetic implications that may affect the patient psychologically and socially, and treatment can be challenging, according to Ana Kaminsky, M.D., Ph.D., professor of dermatology, School of Medicine, University of Buenos Aires, Argentina.
Trial HSV-2 vaccines show promise
April 1st 2005Washington — Clinical studies have already demonstrated proof of concept for both prophylactic and therapeutic vaccines for herpes simplex virus (HSV)-2. Both types of HSV-2 vaccines are currently under development and the next few years should bring promising results, accordingto Lawrence R. Stanberry, M.D., Ph.D., chairman of the department of pediatrics and director of the Sealy Center for Vaccine Development at the University of Texas Medical Branch in Galveston.
Newer antibiotics potent weapons
April 1st 2005Aruba — Newer antibiotics with novel mechanisms of action offer activity against drug-resistant gram-positive organisms and are important additions to the dermatologist's therapeutic arsenal for treating cutaneous infections, according to Bernardo Vainrub, M.D., consultant in internal medicine and infectious diseases, Hospital de Clinicas, Caracas, Venezuela.
Clearance rates high, durable after 5-ALA PDT, study finds
April 1st 2005New Orleans — Results of a multicenter phase 4 study confirm the efficacy and safety of photodynamic therapy (PDT) using 20 percent 5-aminolevulinic acid (5-ALA) topical solution (Levulan Kerastick, DUSA) for the treatment of face and scalp non-hyperkeratotic actinic keratoses (AKs), according to Eduardo H. Tschen, M.D., who spoke at the 63rd Annual Meeting of the American Academy of Dermatology (AAD).
Petition prompts changes in AAD workforce initiative
April 1st 2005National report — Member discontent over the handling of the American Academy of Dermatology's (AAD) workforce initiative unveiled last fall is bringing about fundamental changes in the program — and perhaps in the decision-making process that governs such matters.
Does industry funding jeopardize objectivity?
April 1st 2005New Orleans — Recent research shows that the pharmacy and medical equipment industries influence a physician's practice, education and research, according to Jeffrey J. Meffert, M.D., program director of the dermatology program of the San Antonio Uniformed Services Health Education Consortium.
FDA board to protect patients, update docs
April 1st 2005Washington — Scorched by controversy over how it approves prescription drugs for the marketplace, the U.S. Food and Drug Administration (FDA) is preparing to establish an independent Drug Safety Oversight Board (DSB) to monitor FDA-approved pharmaceuticals and update physicians and patients when new information becomes available.
Too few antibiotics in pipeline
April 1st 2005A public health crisis is brewing, according to a white paper issued by the Infectious Diseases Society of America (IDSA), as two trends converge: the retreat of large and small pharmaceutical companies from antibiotic discovery and development, and the emergence of pathogens with resistance to an increasingly wide spectrum of currently approved antibiotics.
The Expanding Role of 5-FU in Dermatology (PDF)
April 1st 2005Recently, a group of leading dermatologists, clinical investigators, and dermasurgeons met to discuss the role of 5-fluorouracil (5-FU) in their practices. The experts discussed a new treatment paradigm for actinic keratosis (AK) and how it is changing. They also shared their personal experiences in using 5-FU innovatively to treat AK, while reducing inflammation and discomfort and improving compliance. In addition, the physicians reviewed the use of 5-FU in the treatment of several other dermatologic conditions, such aswarts and actinic cheilitis.
Ethics demands declining Superbowl tickets
March 1st 2005Dr. Dave and his friend Steve have known each other since ninth grade. They attended each other's weddings and have been together for many of life's good and bad moments. Steve also represents a publicly traded company that makes pharmaceutical products used by dermatologists.